

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* ARMISTICE CAPITAL, LLC (Last) (First) (Middle) 510 MADISON AVENUE, 7TH FLOOR (Street) NEW YORK, NY 10022 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year) 11/14/2018		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
4. If Amendment, Date Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/14/2018		P		5,129	A	\$ 0.451	16,807,629	D (1)	
Common Stock	11/14/2018		P		0	A	\$ 0	16,807,629	I	See Footnote (2)
Common Stock	11/14/2018		P		0	A	\$ 0	16,807,629	I	See Footnote (2)
Common Stock	11/14/2018		P		50,000	A	\$ 0.4071	16,857,629	D (1)	
Common Stock	11/14/2018		P		0	A	\$ 0	16,857,629	I	See Footnote (2)
Common Stock	11/14/2018		P		0	A	\$ 0	16,857,629	I	See Footnote (2)
Common Stock	11/15/2018		P		126,735	A	\$ 0.434 (6)	16,984,364	D (1)	
Common Stock	11/15/2018		P		0	A	\$ 0	16,984,364	I	See Footnote (2)
Common Stock	11/15/2018		P		0	A	\$ 0	16,984,364	I	See Footnote (2)
Common Stock	11/16/2018		P		178,136	A	\$ 0.47 (7)	17,162,500	D (1)	
Common Stock	11/16/2018		P		0	A	\$ 0	17,162,500	I	See Footnote (2)
Common Stock	11/16/2018		P		0	A	\$ 0	17,162,500	I	See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants	\$ 0.32	11/16/2018		P		625,000		04/17/2018 (4)	04/17/2023	Common Stock	625,000	\$ 0.13	625,000	D (1)	

Warrants	\$ 0.32	11/16/2018		P	0	04/17/2018 ⁽⁴⁾	04/17/2023	Common Stock	0	\$ 0	625,000	I	See Footnote (2)
Warrants	\$ 0.32	11/16/2018		P	0	04/17/2018 ⁽⁴⁾	04/17/2023	Common Stock	0	\$ 0	625,000	I	See Footnote (2)
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	5,468,750		5,468,750	D (1)	
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	0		5,468,750	I	See Footnote (2)
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	0		5,468,750	I	See Footnote (2)
Warrants	\$ 1.5					06/14/2017 ⁽⁴⁾	06/14/2022	Common Stock	2,000,000		2,000,000	D (1)	
Warrants	\$ 1.5					06/14/2017 ⁽⁴⁾	06/14/2022	Common Stock	0		2,000,000	I	See Footnote (2)
Warrants	\$ 1.5					06/14/2017 ⁽⁴⁾	06/14/2022	Common Stock	0		2,000,000	I	See Footnote (2)
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	15,937,500		15,937,500	D (1)	
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	0		15,937,500	I	See Footnote (2)
Warrants	\$ 0.32					04/17/2018 ⁽³⁾	04/17/2023	Common Stock	0		15,937,500	I	See Footnote (2)
Series C Convertible Preferred Stock	\$ 0.32					04/17/2018 ⁽⁵⁾	(5)	Common Stock	12,787,500		12,787,500	D (1)	
Series C Convertible Preferred Stock	\$ 0.32					04/17/2018 ⁽⁵⁾	(5)	Common Stock	0		12,787,500	I	See Footnote (2)
Series C Convertible Preferred Stock	\$ 0.32					04/17/2018 ⁽⁵⁾	(5)	Common Stock	0		12,787,500	I	See Footnote (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ARMISTICE CAPITAL, LLC 510 MADISON AVENUE 7TH FLOOR NEW YORK, NY 10022	X	X		
Armistice Capital Master Fund Ltd. C/O DMS CORPORATE SERVICES LTD. 20 GENESIS CLOSE, P.O. BOX 314 GRAND CAYMAN, E9 KY1-1104		X		
Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022	X	X		

Signatures

Armistice Capital, LLC, By: /s/ Steven Boyd, Managing Member	11/16/2018
^{**} Signature of Reporting Person	Date
Armistice Capital Master Fund Ltd., By: /s/ Steven Boyd, Director	11/16/2018
^{**} Signature of Reporting Person	Date
By: /s/ Steven Boyd	11/16/2018

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reported securities are directly owned by Armistice Capital Master Fund Ltd.

The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice

(2) Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

(3) These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd. from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise.

(4) These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd. from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Shares following such exercise.

The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of Armistice Capital Master Fund, Ltd., subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd. from converting the Series C Convertible Preferred Stock into Common Shares if it would be more than a 4.99% beneficial owner of the Common Shares following such conversion.

(6) This constitutes the weighted average purchase price. The prices range from \$0.4305 to \$0.4431. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

(7) This constitutes the weighted average purchase price. The prices range from \$0.4615 to \$0.4834. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.